1 Introduction
COVID-19 (coronavirus disease 2019) was first reported in China on 31 December 2019. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is an enveloped positive-sense RNA virus, that belongs to the family Coronaviridae (1, 2). The infection starts from pneumonia-like symptoms but later leads to lung damage, causing ground-glass opacity lesions (3).
Unfortunately, the SARS-CoV-2 virus is mutating all the time, leading to the origination of the new virus lineages with different genetic variations. Hence, different lineages of virus have different characteristics: some of them may be relatively harmless, and others are more dangerous, as they can spread more easily or be resistant to treatment. Therefore, SARS-CoV-2 lineages are marked as variants under monitoring, variants of interest, and variants of concern (4). On 15 March 2023 World Health Organization (WHO) has updated the definitions of virus variants and the primary actions for particular classification (5). On 30 March 2023, there was one SARS-CoV-2 lineage defined as a variant of interest—XBB.1.5, and there were seven lineages defined as variants under monitoring, namely, BA.2.75, CH.1.1, BQ.1, XBB, XBB.1.16, XBB.1.9.1, and XBF (6).
The start of COVID-19 was the time around the Lunar New Year celebrations in China, which was associated with an increased number of travelers. Therefore, travel restrictions and large social gatherings have been introduced (7). Moreover, through a large number of rigorous public health measures and diagnostic tests, China had almost repressed the domestic transmission of COVID-19 (8). Generally, there were unusually low death counts and effective suppression of COVID-19 spread in South-East and East Asia in comparison to Western countries before the appearance of COVID-19 vaccines. This was explained by the presence of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics in the past few years. Hence, public health systems in this region were better prepared for similar events (9). However, a rapid increase in daily new COVID-19 cases was observed in China from November to December 2022 (10). Therefore, we decided to analyze the factors that have been related to COVID-19 in China since the beginning of the COVID-19 pandemic.
4 Discussion
In our cross-sectional study, we analyzed the influence of variables pertaining to the number of new COVID-19 cases in China from the beginning of the COVID-19 pandemic. Each year had different profiles and can be described by different variables. Year 2020 was characterized by restrictions, such as international travel controls, stay at home requirements, and health system policies including contact tracing and protection of older adults. Year 2021 was described by SARS-CoV-2 variants, such as Alpha, Beta, Gamma, and Delta, while year 2022 was characterized by new cases per million, Omicron lineages, and few restriction variables. On the other hand, the beginning of 2023 was mainly described by new deaths per million and Omicron variant 22B (BA.5) but also by testing and vaccination policies and the number of people fully vaccinated per 100 and total boosters per 100.
Following the discovery of SARS-CoV2, a novel member of the family Coronaviridae, in early January 2020, China responded with an emergency containment strategy. At the time, the COVID-19 vaccines, treatment, as well as effective operating procedures were unknown. Thus, China, similarly to other countries, focused on the control of viral transmission, monitoring cases of COVID-19, and protection of high-risk groups via NPI (non-pharmaceutical interventions) (17). The crucial factors that affected the effectiveness of NPI measures in China were the rapid introduction of the containment strategy, and sociocultural factors that resulted in social obedience toward governmental policies. Generally, one of the important tools, which used to deter the spread of the virus and identify the contacts between people, is contact tracing. One of the classes of this system based on GPS or location data is the color-based health QR code system which is an innovative system in China. This system classified people through collecting basic information about personal data, travel information, and COVID-19-related information, such as symptoms, vaccination, and results of PCR tests. Then, every individual was classified into a category based on the level of transmission risk using three colors of QR code—green, yellow, and red. Because of privacy data security measures, China introduced some protective measures for privacy in this system (18). Chen et al. (19) in their study claimed that a strategy involving the isolation of infected subjects, disinfection, and health maintenance is crucial for the reduction of the COVID-19 death toll. The above strategy, if implemented properly, was expected to reduce COVID-19-related deaths by 85% in 2020 and by more than 99% in 2022. Moreover, psychosocial problems have become more acute by the outbreak of COVID-19. The study, conducted among Chinese adolescents of 12–18 years, showed that the rates of depression and anxiety symptoms were 43.7% and 37.4%, respectively. Being a senior high school student, residence in Hubei province and female gender were the factors predisposing to developing these symptoms according to multivariable logistic regression analysis (20). However, the prevalence of depression and anxiety symptoms was lower among undergraduates. A higher incidence of developing depression symptoms was observed among the students who were quarantined or isolated while anxiety symptoms were more common among the students whose relatives and friends suffered from COVID-19 (21). Moreover, patients diagnosed with COVID-19 had a higher prevalence of mental problems, insomnia, depression, and anxiety in comparison to non-infected controls (22). Social media exposure was also associated with mental health problems among Chinese citizens (23). Obviously, medical health workers had a higher rate of insomnia, anxiety, depression, somatization, and obsessive-compulsive symptoms when compared with non-medical health workers, as shown in a cross-sectional study conducted in China from 19 February 2020 to March 6, 2020 (24).
In the later stages of the pandemic, a crucial role in restricting the number of COVID-19 cases or deaths is COVID-19 vaccination. According to a survey study conducted among employees of a Chinese geriatric care facility, the respondents possessed were relatively familiar with the topic of COVID-19 vaccines, and the vast majority of them were willing to be vaccinated (25). Medium level of vaccine-related knowledge has been noted among Chinese small-town residents. Moreover, most of the studied population wore masks outside and expressed an optimistic attitude toward the end of the pandemic (26). A survey study conducted on subjects suffering from rheumatoid arthritis confirmed the positive attitude of Chinese society toward the vaccination program, although it pointed out the low availability of vaccine doses as less than half of those willing to participate were vaccinated (27). A cross-sectional study that was conducted on adolescents from three Chinese provinces showed a high level of acceptance rate of COVID-19 vaccination. Only 1.6% of participants have declined the COVID-19 vaccination, mainly due to safety concerns of COVID-19 vaccines (28).
Pan et al. (29) described the contribution of particular SARS-CoV-2 variants to the epidemiological situation in China in 2022. Until November 2022, in Beijing, the dominant variants included Omicron BA.2.2.1, BF.7, and BA.5.2, whereas after mid-November, the dominant variant switched to the clade 22B, predominantly BF.7. Moreover, they observed that the infection peak caused by Omicron sub-variant correlated with the number of flights arrived to Beijing. In January 2022, Omicron sub-variant BA.2 caused COVID-19 cases in Hong Kong. Three doses of BNT162b2 and CoronaVac vaccines have protected against severe and fatal COVID-19 infections (30).
At the end of 2022, there were mass protests in China against zero-COVID policy, according to media news (31–35). The zero-COVID policy has been the foundation of the anti-pandemic strategy in China. However, the lockdowns in the country had negative effects, such as disruption of the economy or food shortage but also difficulties in accessing medical care. Moreover, low morbidity of COVID-19 caused low level of natural immunity in the Chinese population. On the other hand, vaccination hesitancy resulted from no urgent need for vaccination. All of these raise questions about the effectiveness of this policy (36, 37). Because of the spread of the Delta variant, in August 2021, China introduced a novel strategy entitled “Dynamic COVID-zero”, which aimed to minimize the influence of COVID-19 on different socioeconomic areas and balance this with control and prevention of COVID-19 (38). Because of the high infectivity and low pathogenicity of the Omicron variant, China changed its anti-COVID-19 strategy by introducing 30 anti-COVID-19 measures in two waves, the first on 11 November 2022 (20 measures) and the second on 7 December 2022 (10 measures). The above mentioned changes included e.g., alleviation of travel restriction or shortening of isolation period (39). The end of this strategy, which was difficult to maintain against the Omicron variant, was announced on 7 December 2022 by the National Health Commission of China (40). Potentially, a stepwise withdrawal from the zero-COVID strategy could have been achievable as early as April or May 2022 due to warm temperatures, successful vaccination, and well-developed medical infrastructure (41). On 8 January 2023, the zero-COVID policy was stopped in China, which includes missing contact tracing, centralized quarantine, and mass COVID-19 testing (37). As a result, in order to avoid high level of mortality, quick vaccination of older adults might cause a rapid increase in demand for COVID-19 vaccines. Moreover, a sharp increase in the number of COVID-19 infection cases might cause a collapse in hospital infrastructure due to a lack of trained intensive care unit doctors as well as nurses (42).
Unfortunately, our study has some limitations. Not all of the data in the publicly available databases were complete. Moreover, because of the changes in testing strategy, the actual number of reported COVID-19 cases might be different than official data (37). Despite the fact that these limitations may have affected the results of our analysis, in our study, we showed the important factors related to the COVID-19 pandemic in China.
Although most of the countries adopted similar anti-COVID-19 prevention measures, they had to adapt their strategies according to their individual needs, e.g., economic or healthcare status. European Union (EU) members presented a different attitude toward the COVID-19 pandemic, especially when it came to the general lack of control of cross-border movements between the states and the choice of daily life restrictions and their severity. Moreover, during the COVID-19 pandemic, the crucial factors that affected the number of COVID-19 deaths in EU were the socioeconomic status and the availability of specialized equipment in the medical care facilities (43). Noteworthy, the measures implemented in Europe, similar to the Chinese strategy, have proven to be relatively successful in limiting SARS-CoV-2 spread. Our study pointed out the main factors that influenced the number of COVID-19 cases in the course of the pandemic in China starting from the year 2020 to the beginning of 2023. At the very beginning of the pandemic, the crucial role was played by anti-COVID-19 countermeasures of China, while in the latter stages, the number of cases was affected mostly by the vaccination status and the presence of COVID-19 variants.